Abstract:There is growing interest in the use of preoperative (neoadjuvant) chemotherapy for patients with localized breast cancer. Originally, it was hypothesized that such early use of chemotherapy might improve survival, compared with standard postsurgical adjuvant systemic therapy, but this has not proven to be the case. Nonetheless, the primary tumor response is likely a barometer for tumor sensitivity to therapy and may be used to help guide decisions regarding additional systemic therapy. Furthermore, preoperative chemotherapy can increase the fraction of women eligible for breast-conservation therapy. A seemingly logical extension of this latter observation is the hypothesis that one can further reduce local therapies in patients responding well to initial chemotherapy. For example, studies are under way to omit (or limit) radiotherapy (RT) in patients who present with positive axillary nodes and experience pathologic complete response in the nodes to preoperative chemotherapy (eg, NSABP [National Surgical Adjuvant Breast and Bowel Project] B-51/RTOG [Radiation Therapy Oncology Group] 1304). In the NSABP/RTOG study, patients with involved axillary nodes (histologically confirmed) are treated with neoadjuvant chemotherapy. Those who are node negative at subsequent mastectomy are randomly assigned to postmastectomy RT (PMRT) to the chest wall and regional nodes. Similarly, patients who undergo subsequent breast conservation surgery and whose nodes have become negative after preoperative chemotherapy will be randomly assigned to breast RT regional nodal RT. We appreciate the importance of the question being asked in these studies and support their conduct. Defining patient subgroups that do (or do not) benefit from our therapies is an important goal. It is possible that response to preoperative chemotherapy predicts for the potential benefit of local regional RT (and hence theassociatedtherapeutic ratio).Responders topreoperativechemotherapy may have a lesser need for additional local regional RT. However, we believe the converse may be true: that the potential survival benefits of local therapies are likely highest among responders to preoperative chemotherapy. Consider the more typical clinical scenario for node-positive patients who undergo initial mastectomy, followed by adjuvant chemotherapy (Fig 1). In that setting, the addition of PMRT improves overall survival (OS) by approximately 6% to 9%. This group includes both responders and nonresponders to chemotherapy, althoughidentificationofthesesubgroupsisnotpossible,becausechemotherapy is administered postoperatively. If it is true that responders to neoadjuvant chemotherapy derive lesser survival gains with PMRT, it must follow that nonresponders derive greater gains, because the OS benefit should still be 6% to 9% (ie, sequencing of surgery and chemotherapy should not alter this; Fig 1, lower panel). An analogous situation exists for patients undergoing breast conservation. The NCIC Clinical Trials Group MA.20 study reported improvements in locoregional control and distant disease-free survival and a trend in OS with the addition of nodal RT to breast RT in patients undergoing lumpectomy followed by chemotherapy. If responders to preoperative chemotherapy derive lesser gains with nodal RT, nonresponders should derive greater gains (again, to make the math work). As we discuss here, the evidence suggests that the opposite may be true: namely, that responders to systemic therapy might derive the most survival benefit from RT. Mastectomy Chemotherapy 6%-9%

A New Synthetic Route to Diastereomerically Pure Cyclopropane‐Phosphorus Derivatives Utilizing the Chiron 5‐l‐menthyloxy‐3‐bromo‐2(5h)‐furanone and Racemic Dialkyl Α‐hydroxyalkanephosphonate

Synthesis, structure and anti-tumor activity of spiro[(1-bromo-4-methoxy-5- oxa-6-oxobicyclo[3.1.0]hexane-2,2'-(3- {α-[di(ethoxy)phosphoryl]benzyloxy} -4-methoxy-5-oxa-1-oxocyclopentane]

Reducing local therapy in patients responding to preoperative systemic therapy: are we outsmarting ourselves?

Diastereoselective Synthesis of Α-Stabilized Phosphorus Ylides Via a Four-Component Reaction

Diastereoselective Synthesis of (1S)-Trans-cyclopropane-1,2-dicarboxylic Acid Derivatives Using 1,2;4,5-Di-o-isopropylidene-d-fructopyranose As the Chiral Auxiliary

Near-deBruijn Cycles: 11336 [2008, 71]

Access to Phosphorous-containing Cyclopenta[b]benzofuranols via Bifunctional Phosphonium Salt-promoted Serendipitous Cascade Reaction

Towards Axially Chiral Pyrazole-Based Phosphorus Scaffolds by Dipeptide-Phosphonium Salt Catalysis.

Organocatalytic Enantio- and Diastereoselective Assembly of Cyclopropane-Incorporated Polycyclic Molecules via Isobenzopyrylium Ions

New and efficient approach to the synthesis of pentacoordinate spirobicyclic phosphoranes

Palladium-catalyzed Stereoselective Decarboxylative [4 + 2] Cyclization of 2-Methylidenetrimethylene Carbonates with Pyrrolidone-Derived Enones: Straightforward Access to Chiral Tetrahydropyran-Fused Spiro-Pyrrolidine-2,3-diones

Asymmetric Palladium-Catalyzed Decarboxylative [3+2] Cycloaddition: Straightforward Construction of Chiral Spiro-Heterocyclic Scaffolds

A Desymmetric Dearomatization Cyclopropanation of [2.2]Paracyclophane

Direct Functionalization of White Phosphorus to Cyclotetraphosphanes: Selective Formation of Four P-C Bonds

Efficient Asymmetric Synthesis of P-chiral Phosphine Oxides Via Properly Designed and Activated Benzoxazaphosphinine-2-oxide Agents.

Organocatalytic Dynamic Kinetic Resolution Enabled Asymmetric Synthesis of Phosphorus-Containing Chiral Helicenes.

Peer review report 1 on "Apelin attenuates postburn sepsis via a phosphatidylinositol 3-kinase/protein kinase B dependent mechanism: A randomized animal study".

Phosphine-Catalyzed Diastereo- and Enantioselective Michael Addition of β-Carbonyl Esters to β-Trifluoromethyl and β-Ester Enones: Enhanced Reactivity by Inorganic Base

Facile Synthesis of Alkylphosphonates from 4-Alkyl-1,4-Dihydropyridines via Photoinduced Formal Deformylative Phosphonylation

Stereoselective Rh2(S-IBAZ)4-catalyzed cyclopropanation of alkenes, alkynes, and allenes: asymmetric synthesis of diacceptor cyclopropylphosphonates and alkylidenecyclopropanes.

Stereodivergently asymmetric synthesis of chiral phosphorus compounds by synergistic combination of ion-pair catalyst and base